Compare CVS Health Corp (CVS) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Li Auto Inc — how do they compare? CVS Health Corp trades at $87.04 (market cap $112.29B), while Li Auto Inc trades at $11.56 (market cap $10.71B). The key difference: CVS Health Corp is far larger — about 10.5× Li Auto Inc's market cap, and CVS Health Corp pays a 3.03% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Li Auto Inc for 101 Days on average.
| CVS | LI | |
|---|---|---|
Market Cap | $112.29B | $10.71B |
Volume | 7,763,676 | 1,781,143 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $23.61 |
52-Week Low | $70.08 | $10.69 |
Typical Hold Time | 83 Days | 101 Days |
Enterprise Value | $174.64B | $139.58M |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.
CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.
Li Auto (LI) trades at $11.61, down 5.64% on the day and near 52-week lows amid delivery concerns. The technical picture is bearish with negative moving averages, while fundamentals show revenue declining from $144.5B in 2024 to $112.3B in 2025, though the company maintains a strong balance sheet with $112.8B cash. Recent Q2 2026 earnings missed expectations with a net loss of $0.25 per share, and September deliveries of 31,817 vehicles indicate volume moderation.
The outlook remains challenging with intense EV competition and margin pressure, but analyst consensus suggests 31% upside to the $15.18 price target. Key risks include execution on new model launches (Li i9, MEGA) and China's auto market slowdown, while the company's cash position provides buffer against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
